S-J Dawson
Overview
Explore the profile of S-J Dawson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
952
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beaumont S, Angel C, Dawson S
Aust Dent J
. 2022 Jan;
67(2):183-189.
PMID: 34978350
This case report describes an adverse side effect from long-term denosumab therapy in a patient with metastatic breast cancer. The patient presented with extensive invasive cervical root resorption affecting most...
2.
Hollizeck S, Wong S, Solomon B, Chandrananda D, Dawson S
Bioinformatics
. 2021 Sep;
37(21):3916-3919.
PMID: 34469518
Summary: This work describes two novel workflows for variant calling that extend the widely used algorithms of Strelka2 and FreeBayes to call somatic mutations from multiple related tumour samples and...
3.
Tan L, Sandhu S, Lee R, Li J, Callahan J, Ftouni S, et al.
Ann Oncol
. 2019 Mar;
30(5):804-814.
PMID: 30838379
Background: The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the cost and toxicities associated...
4.
Ali H, Glont S, Blows F, Provenzano E, Dawson S, Liu B, et al.
Ann Oncol
. 2015 Apr;
26(7):1488-93.
PMID: 25897014
Background: Expression of programmed death ligand 1 (PD-L1) in solid tumours has been shown to predict whether patients are likely to respond to anti-PD-L1 therapies. To estimate the therapeutic potential...
5.
Ignatiadis M, Dawson S
Ann Oncol
. 2014 Oct;
25(12):2304-2313.
PMID: 25336116
Next-generation sequencing studies have provided further evidence to support the notion that cancer is a disease characterized by Darwinian evolution. Today, we often fail to capture this evolution and treatment...
6.
Ali H, Provenzano E, Dawson S, Blows F, Liu B, Shah M, et al.
Ann Oncol
. 2014 Jun;
25(8):1536-43.
PMID: 24915873
Background: T-cell infiltration in estrogen receptor (ER)-negative breast tumours has been associated with longer survival. To investigate this association and the potential of tumour T-cell infiltration as a prognostic and...
7.
Ali H, Irwin M, Morris L, Dawson S, Blows F, Provenzano E, et al.
Br J Cancer
. 2013 Jan;
108(3):602-12.
PMID: 23329232
Background: High-throughput evaluation of tissue biomarkers in oncology has been greatly accelerated by the widespread use of tissue microarrays (TMAs) and immunohistochemistry. Although TMAs have the potential to facilitate protein...
8.
Ali H, Dawson S, Blows F, Provenzano E, Pharoah P, Caldas C
Br J Cancer
. 2012 Apr;
106(11):1798-806.
PMID: 22538974
Background: Proliferation has emerged as a major prognostic factor in luminal breast cancer. The immunohistochemical (IHC) proliferation marker Ki67 has been most extensively investigated but has not gained widespread clinical...
9.
Ali A, Dawson S, Blows F, Provenzano E, Ellis I, Baglietto L, et al.
Br J Cancer
. 2011 Jan;
104(4):693-9.
PMID: 21266980
Background: Tissue micro-arrays (TMAs) are increasingly used to generate data of the molecular phenotype of tumours in clinical epidemiology studies, such as studies of disease prognosis. However, TMA data are...
10.
Dawson S, Makretsov N, Blows F, Driver K, Provenzano E, Le Quesne J, et al.
Br J Cancer
. 2010 Jul;
103(5):668-75.
PMID: 20664598
Background: Breast cancer is heterogeneous and the existing prognostic classifiers are limited in accuracy, leading to unnecessary treatment of numerous women. B-cell lymphoma 2 (BCL2), an antiapoptotic protein, has been...